News


  • 12 November 2014

    Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

    Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

    Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Because tumor biopsy material is often limited in lung cancer patients, Epic developed a new assay that detects PD-L1 protein on CTCs in a blood sample. 

  • 21 October 2014

    Epic Sciences Appoints Michael Giske as Chief Information Officer

    Epic Sciences Appoints Michael Giske as Chief Information Officer

    Epic Sciences announced the appointment of Michael Giske as chief information officer. Mr. Giske has more than 25 years of defining, designing and implementing secure, global, large-scale technology solutions to deliver innovative and impactful products. At Epic, he will lead the IT strategy and execution for the company’s diagnostics platform, which includes Epic’s circulating tumor cell (CTC) technology. 

  • 16 October 2014

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    As part of the Panel Discussion “Optimal Strategies and Exit Models for Venture Investors” held during 3rd Moscow International Forum for Innovative Development “Open Innovations” Evgeny Zaytsev shared his experience of various exit models from venture investments in biotech.

  • 16 October 2014

    Open Innovations: Professional venture capital management is key - Evgeny Zaytsev

    Open Innovations: Professional venture capital management is key - Evgeny Zaytsev

    “Venture capital industry, if not financially supported by the government, would take a long time to develop in Russia”, - said Dr. Evgeny Zatsev, Managing Partner, RMI Partners, Moderator of the Panel Discussion “Russian Venture Capital at the Point of the Local Extremum” held on November 14 as part of the III International Forum “Open Innovations”. Evgeny shared his view on various issues raised in the panel discussion.

  • 16 October 2014

    Generation S: Young entrepreneurs are the driving force of innovation

    Generation S: Young entrepreneurs are the driving force of innovation

    The III Moscow Open Innovations Forum was a venue of the Award ceremony to recognize the winners of the start-up contest GenerationS. The GenerationS finalists in four nominations were selected by a panel of judges comprised of 100 Russian and international investors. The total of 25 best projects in IT, Industrial, BiotechMed and CleanTech qualified for the finals. Dr. Evgeny Zaytsev, Managing Partner, RMI Partners was a judge for BioTechMed and shared his view on the development of Russian biotech startup companies.

  • 15 October 2014

    Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

    Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

    Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis. In the phase 1/2 clinical study, eight patients diagnosed with non-infectious uveitis at three U.S. study centers received a single suprachoroidal injection of a formulation of preservative-free triamcinolone acetonide injectable suspension using Clearside’s proprietary microinjector. 

  • 25 September 2014

    Horus Pharma and NovaMedica sign agreement to market a portfolio of eye care products in Russia

    Horus Pharma and NovaMedica sign agreement to market a portfolio of eye care products in Russia

    NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS). 

  • 15 September 2014

    Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

    Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

    Epic Sciences announced today the appointment of Glen Paul Freiberg, RAC as vice president of regulatory affairs and quality assurance. Mr. Freiberg has more than 35 years of FDA-related experience and is recognized as a key leader in successful regulatory and compliance strategies for diagnostic products. Epic’s circulating tumor cell (CTC) technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy, selection and early drug resistance detection to improve the treatment of cancer.

  • 04 September 2014

    Clearside Biomedical, Inc. Announces Fourth Patent Allowance in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

    Clearside Biomedical, Inc. Announces Fourth Patent Allowance in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

    Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S. Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices.

  • 01 September 2014

    Clearside Biomedical, Inc. Completes $16 Million Series B Financing

    Clearside Biomedical, Inc. Completes $16 Million Series B Financing

    Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.